• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[히트뉴스] 히터뷰 | CAR-T 치료제 개발 위해 ‘국내 첫 임상’ 시작한 큐로셀[히트뉴스]

2021/03/08

히터뷰 | CAR-T 치료제 개발 위해 ‘국내 첫 임상’ 시작한 큐로셀 < 피플 < 기사본문 – 히트뉴스 (hitnews.co.kr)

Prev[한경 BIO Insight] [Cover Story – part.5] 큐로셀, CAR-T 뛰어넘는 CAR-T 개발
Next큐로셀, CAR-T치료제 임상1·2상 개시…”국내 첫 환자 투여”
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.